Evidence mapPaperPMID 41264887Full record

ArticleJournal of proteome research2025

Targeted Metabolomic Methods for

Erin Q Jennings, W Kimryn Rathmell, Jeffrey C Rathmell

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Erin Q JenningsNational Institute of Digestive and Diabetes and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID 0000-0002-6991-6098
W Kimryn RathmellPreviously, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.ORCID 0000-0002-4984-0225
Jeffrey C RathmellDepartment of Pathology, Microbiology and Immunology, Division of Molecular Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.

Funding

BIOCHEMICAL &CHEMICAL TRAINING FOR CANCER RESEARCHT32CA009582 · VANDERBILT UNIVERSITY · 1987 to 2025
$2.2M
Metabolic barriers to T cell activation in clear cell renal cell carcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · 2023 to 2025
$1.1M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Shankar Subramaniam · 2020 to 2020
$500k
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$407k
Intramural NIH HHS Z99 DK999999NCI NIH HHS R01 CA217987NCI NIH HHS T32 CA009582NIDDK NIH HHS R01 DK105550NIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544
6 · The paper itself

Abstract

Heavy carbon labeling has emerged as a popular way to study metabolic diseases. However, most carbon labeling techniques use untargeted mass spectrometry, which typically requires dependence on a research core and specialized software. By combining published

Indexed as

GlucoseGlutamineIsotope LabelingMetabolomicsTandem Mass SpectrometryCarbon IsotopesChromatography, LiquidCitric Acid CycleGlycolysisHumansLiquid Chromatography-Mass SpectrometryCarbon-13Carbon IsotopesGlucoseGlutaminecarbon tracingstable isotope labelingtandem mass spectrometrytargeted metabolomics

Identifiers

PMID41264887
PMCPMC12704460

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.